Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SNR3C2
The experimentally established mechanism targets of Nimodipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 9/20 | 0.82 |
| ▸ | CACNA1F known ✓ | O60840 | 8/20 | 0.82 |
| ▸ | CACNA1D known ✓ | Q01668 | 8/20 | 0.82 |
| ▸ | CACNA1S known ✓ | Q13698 | 8/20 | 0.82 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nimodipine SCHEMBL29382758 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL30425942 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL8531069 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| (S)-Nimodipine SCHEMBL34042 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL4530304 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL27757251 | 0.99 | MEN1 (0.98) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL27608151 | 0.99 | MEN1 (0.98) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL142534 | 0.99 | MEN1 (0.98) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL28487234 | 0.97 | MEN1 (0.94) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| Nimodipine SCHEMBL26110731 | 0.97 | MEN1 (0.94) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 36192 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| US-20260124186-A1 | Nimodipine Parenteral Administration | ACASTI PHARMA U.S., INC. (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724060-A1 | FORMULATIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HB Biotech, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4704904-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260053863-A1 | ACELLULAR ALLOGENIC EXOSOME PREPARATIONS AND METHODS OF USE | NEUROCYTE PTE LTD (AU) | 2026-02-26 | — | — | US | claimed |
| CN-85102334-A | The method for preparing dihydropyridine preparation | — | 1987-01-24 | — | — | CN | claimed |
| EP-0126315-B1 | PARENTERAL FORMULATION OF NIMODIPIN, PROCESS FOR ITS PREPARATION AND ITS THERAPEUTICAL USE | BAYER AG (DE) | 1987-01-14 | — | — | EP | claimed |
| EP-0204951-A2 | Use of calcium channel blockers in the production of compositions for withdrawal symptoms | MILES INC. (US) | 1986-12-17 | — | — | EP | claimed |
| CN-85109017-A | The preparation technology of different dihydropyridine mixture and the purposes aspect medical thereof | — | 1986-08-27 | — | — | CN | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| US-4537898-A | WITH POLYOXYETHYLENE GLYCOL DERIVATIVES AS SOLUBILIZERS | BAYER AKTIENGESELLSCHAFT (DE) | 1985-08-27 | — | — | US | claimed |
| US-4520112-A | RADIOACTIVE LABELING | THE JOHNS HOPKINS UNIVERSITY (US) | 1985-05-28 | — | — | US | claimed |
| US-4504476-A | Method of administering calcium channel blocking agents | SCHWARTZ ARNOLD | 1985-03-12 | — | — | US | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| EP-0123850-A2 | Inhibition of tumor growth and metastasis with calcium channel blocker compounds | THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1984-11-07 | — | — | EP | claimed |